Menu

FDA: Lab Tests Can Cause Harm

The US Food and Drug Administration cites cases in which laboratory-developed tests “may have caused or have caused actual harm to patients.”

Nov 17, 2015
Tracy Vence

PIXABAY, OPENCLIPARTVECTORSLaboratory-developed tests (LDTs), which are classified as in-vitro diagnostics by the US Food and Drug Administration (FDA), are clinical tools designed, manufactured, and used by a single lab. While LDTs are subject to the Federal Food, Drug, and Cosmetic (FD&C) Act, and therefore fall under FDA’s jurisdiction, the agency has “generally used its enforcement discretion to not enforce the device provisions of the FD&C Act for LDTs,” the agency explained in a November 16 report. Labs that design, manufacture, and use LDTs—including, for example, those employed by California firms Theranos and Pathway Genomics—must adhere to the regulatory requirements of Clinical Laboratory Improvement Amendments (CLIA). But CLIA certification might not be enough, according to the FDA, which this week described 20 cases in which LDTs “may have caused or have caused actual harm to patients.”

In its report, the FDA highlighted false-positives and false-negatives among several potentially harmful test results. Among the LDTs covered in FDA’s report are ovarian cancer screening tests, Lyme disease and whooping cough diagnostics, and noninvasive prenatal tests to detect fetal chromosomal abnormalities. “Other LDTs provided information with no proven relevance to the disease or condition for which they are intended for use, while still others are linked to treatments based on disproven scientific concepts,” the agency noted. “In addition to patient harm, inaccurate or unreliable tests can be costly to society.”

The FDA last year said it would begin regulating LDTs through a process the agency plans to phase in over time. “FDA oversight would help ensure that tests are supported by rigorous evidence, that patients and health care providers can have confidence in the test results, and that LDTs have more scientifically accurate product labeling,” Peter Lurie, associate commissioner for Public Health Strategy and Analysis at FDA, wrote in a November 16 blog post.

Hat tip: The Wall Street Journal

April 2019

Will Car T Cells Smash Tumors?

New trials take the therapy beyond the blood

Marketplace

Sponsored Product Updates

Application of TruBIOME™ to Increase Mouse Model Reproducibility
Application of TruBIOME™ to Increase Mouse Model Reproducibility
With this application note from Taconic, learn about the effects of the microbiome on reproducibility and predictability and how TruBIOME™ helps researchers generate custom microbiota mouse models!
Getting More Consistent Results by Knowing the Quality of Your Protein
Getting More Consistent Results by Knowing the Quality of Your Protein
Download this guide from NanoTemper to learn how to identify and evaluate the quality of your protein samples!
Myth Busting: The Best Way to Use Pure Water in the Lab
Myth Busting: The Best Way to Use Pure Water in the Lab
Download this white paper from ELGA LabWater to learn about the role of pure water in the laboratory and the advantages of in-house water purification!
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu Corporation announces the release of the Nexera Ultra High-Performance Liquid Chromatograph series, incorporating artificial intelligence as Analytical Intelligence, allowing systems to detect and resolve issues automatically. The Nexera series makes lab management simple by integrating IoT and device networking, enabling users to easily review instrument status, optimize resource allocation, and achieve higher throughput.